AZULIX 3MF TAB

Distributor inventory | Tablet

Treatment of type 2 diabetes mellitus in adults when blood sugar is not adequately controlled with diet, exercise and/or other antidiabetic medicines; helps control fasting and post‑meal glucose and improve insulin sensitivity.

Glimepiride (a sulfonylurea) increases insulin release from pancreatic beta cells. Metformin reduces hepatic glucose production and improves peripheral insulin sensitivity. Pioglitazone (a thiazolidinedione) improves insulin sensitivity in muscle and adipose tissue via PPAR‑γ activation.

Oral tablet; take exactly as prescribed. Usually taken once daily with or immediately after food (often with breakfast) to reduce stomach upset and risk of low sugar; swallow whole (do not crush/chew if modified/extended release). Monitor blood glucose regularly.

Hypoglycaemia, dizziness, headache, nausea, diarrhoea, abdominal pain, metallic taste, weight gain, oedema (swelling), fatigue

Prescription only. Risk of hypoglycaemia (especially if meals are skipped, alcohol use, or with other antidiabetics); carry glucose. Metformin: risk of lactic acidosis—avoid in severe kidney impairment, severe liver disease, dehydration, sepsis, hypoxia; stop temporarily around major surgery or iodinated contrast as advised. Pioglitazone: may cause fluid retention/worsen heart failure; avoid in NYHA class III/IV heart failure; monitor for weight gain/oedema. Possible risk of fractures and rare bladder cancer—avoid in active bladder cancer/ unexplained hematuria. Monitor kidney function, liver enzymes, and blood glucose/HbA1c. Not for type 1 diabetes or diabetic ketoacidosis.